Kähönen M, Ylitalo R, Kööbi T, Turjanmaa V, Ylitalo P
Department of Pharmacological Sciences, University of Tampere, Finland.
Int J Clin Pharmacol Ther. 1998 Sep;36(9):483-9.
The effects of antihypertensive agents on cardiovascular parameters, especially on arterial pulse wave velocity, remain largely unknown in normotensive subjects. Therefore, the present investigation was designed to evaluate acute effects of ACE inhibitor captopril,beta-adrenoceptor blocker propranolol and calcium entry blocker verapamil on cardiovascular and ventilatory function in healthy volunteers.
The influence of single doses of captopril (25 mg), propranolol (40 mg), and verapamil (80 mg) on cardiovascular function and exercise capacity were compared in healthy volunteers in a randomized, double-blind, placebo-controlled fashion.
Cardiac output and beat-by-beat blood pressure were estimated non-invasively before and after the drug administrations by whole-body impedance cardiography and Finapres finger blood pressure monitoring, respectively. Arterial pulse wave velocity was obtained from the time delay between flow pulses measured from the root of the aorta and the popliteal artery, and systemic vascular resistance was calculated from cardiac output and mean arterial pressure. In addition, a progressive maximal exercise test was performed after the treatments.
Propranolol reduced heart rate, cardiac output and arterial pulse wave velocity, and increased systemic vascular resistance clearly more effectively than placebo. In addition, captopril effectively decreased arterial resistance and pulse wave velocity. However, the influence of verapamil on cardiovascular parameters did not significantly differ from those observed in placebo-treated subjects. Exercise peak heart rate, peak blood pressure, and minute ventilation were reduced in subjects treated with propranolol, but not in those treated with captopril and verapamil, when compared to placebo.
Acute administration of captopril and propranolol but not verapamil clearly modulated cardiovascular parameters in rest, suggesting differential effects of these compounds on cardiovascular function in healthy volunteers. These drugs seem to have disparate effects on arterial pulse wave propagation as an indicator of arterial compliance after short-term administration in healthy subjects. Captopril and verapamil had no effect on cardiovascular and ventilatory function during maximal exercise, while propranolol markedly altered also these variables in the present study.
降压药物对心血管参数的影响,尤其是对动脉脉搏波速度的影响,在血压正常的受试者中仍大多未知。因此,本研究旨在评估血管紧张素转换酶抑制剂卡托普利、β肾上腺素受体阻滞剂普萘洛尔和钙通道阻滞剂维拉帕米对健康志愿者心血管和通气功能的急性影响。
以随机、双盲、安慰剂对照的方式,比较了单剂量卡托普利(25毫克)、普萘洛尔(40毫克)和维拉帕米(80毫克)对健康志愿者心血管功能和运动能力的影响。
分别通过全身阻抗心动图和Finapres手指血压监测,在给药前后无创估计心输出量和逐搏血压。动脉脉搏波速度通过测量主动脉根部和腘动脉血流脉冲之间的时间延迟获得,全身血管阻力根据心输出量和平均动脉压计算得出。此外,治疗后进行了递增式最大运动试验。
普萘洛尔降低心率、心输出量和动脉脉搏波速度,且比安慰剂更有效地明显增加全身血管阻力。此外,卡托普利有效降低动脉阻力和脉搏波速度。然而,维拉帕米对心血管参数的影响与安慰剂治疗组观察到的影响无显著差异。与安慰剂相比,普萘洛尔治疗的受试者运动峰值心率、峰值血压和分钟通气量降低,但卡托普利和维拉帕米治疗的受试者未降低。
急性给予卡托普利和普萘洛尔而非维拉帕米可明显调节静息时的心血管参数,表明这些化合物对健康志愿者心血管功能的影响存在差异。在健康受试者短期给药后,这些药物似乎对作为动脉顺应性指标的动脉脉搏波传播有不同影响。卡托普利和维拉帕米在最大运动期间对心血管和通气功能无影响,而在本研究中普萘洛尔也明显改变了这些变量。